Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.45    0.00 (0.00%)
Bid:
8.30
Ask:
8.60
Spread: 0.30 (3.614%)
Market Cap: £18.43m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Oct 20099:42 amRNSHolding(s) in Company
14th Oct 20097:00 amRNSResearch Update
18th Aug 20097:00 amRNSInterim Management Statement
23rd Jul 20097:00 amRNSRe Agreement
20th May 20097:00 amRNSInterim Results
11th May 200911:12 amRNSBlocklisting Interim Review
5th May 20099:14 amRNSCPT commits to the development of Cogane
20th Apr 20097:00 amRNSResearch Update
13th Mar 20099:58 amRNSResult of AGM
10th Mar 20095:16 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:10 pmRNSDirector/PDMR Shareholding
3rd Mar 20095:26 pmRNSAnnual Information Update
19th Feb 20093:42 pmRNSHolding(s) in Company
17th Feb 20094:00 pmRNSHolding(s) in Company
17th Feb 20097:00 amRNSInterim Management Statement
28th Jan 200910:48 amRNSAnnual Report & Accounts and Notice of AGM
19th Dec 20084:41 pmRNSSecond Price Monitoring Extn
19th Dec 20084:37 pmRNSPrice Monitoring Extension
12th Dec 200812:00 pmRNSPortfolio Update
27th Nov 20087:00 amRNSFinal Results
14th Nov 20081:00 pmRNSTrading Statement
13th Nov 20087:00 amRNSBoard Change
11th Nov 200810:09 amRNSDirector/PDMR Shareholding
5th Nov 20081:43 pmRNSBlocklisting Interim Review
9th Oct 20082:45 pmRNSDirector/PDMR Shareholding
10th Sep 20089:27 amRNSDirector/PDMR Shareholding
8th Aug 20083:21 pmRNSDirector/PDMR Shareholding
21st Jul 20084:35 pmRNSPrice Monitoring Extension
9th Jul 20084:40 pmRNSDirector/PDMR Shareholding
3rd Jul 20087:00 amRNSInterim Management Statement
13th Jun 200812:47 pmRNSDirector/PDMR Shareholding
11th Jun 20087:00 amRNSProduct Launch
4th Jun 20085:59 pmRNSTotal Voting Rights
3rd Jun 200810:06 amRNSDirector/PDMR Shareholding
3rd Jun 200810:04 amRNSDirector/PDMR Shareholding
29th May 20087:00 amRNSInterim Results
21st May 20087:00 amRNSMyogane granted European Unio
16th May 200811:32 amRNSNotice of Results
12th May 20082:10 pmRNSDirector/PDMR Shareholding
2nd May 200810:25 amRNSBlocklisting Interim Review
1st May 20089:32 amRNSTotal Voting Rights
14th Apr 200812:14 pmRNSDirector/PDMR Shareholding
14th Apr 200811:58 amRNSHolding(s) in Company
14th Apr 200811:48 amRNSHolding(s) in Company
9th Apr 200810:18 amRNSHolding(s) in Company
4th Apr 20086:08 pmRNSHolding(s) in Company
4th Apr 20086:07 pmRNSHolding(s) in Company
4th Apr 20085:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.